NCT02173392View on ClinicalTrials.gov

A Bioequivalence Study Comparing a Single 1.5mL Dose of Brodalumab vs. Two Doses (1.0mL + 0.5mL) of Brodalumab

PHASE1CompletedINTERVENTIONAL
Enrollment

145

Participants

Timeline

Start Date

September 30, 2014

Primary Completion Date

November 30, 2014

Study Completion Date

December 31, 2014

Conditions
Psoriasis
Interventions
DRUG

Brodalumab

Brodalumab is a large molecule for the treatment of inflammatory diseases

Trial Locations (6)

33180

Research Site, Aventura

55114

Research Site, Saint Paul

68502

Research Site, Lincoln

78209

Research Site, San Antonio

78744

Research Site, Austin

91206

Research Site, Glendale

All Listed Sponsors
lead

Bausch Health Americas, Inc.

INDUSTRY

NCT02173392 - A Bioequivalence Study Comparing a Single 1.5mL Dose of Brodalumab vs. Two Doses (1.0mL + 0.5mL) of Brodalumab | Biotech Hunter | Biotech Hunter